51 results
8-K
EX-10.1
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company
8-K
EX-10.2
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
for the Placement Agent reasonably determines that it would be conflict of interest under the applicable rules of professional responsibility for the same counsel
424B5
erd98iisxe5v5kyav
1 Feb 24
Prospectus supplement for primary offering
4:49pm
8-K
EX-10.1
nvguv7 4v9v7nfsk4p
1 Feb 24
Entry into a Material Definitive Agreement
4:09pm
424B3
o1e grh50tt7hns85
4 Apr 23
Prospectus supplement
4:57pm
POS AM
3iphzm
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
8-K
EX-10.1
yhdwrij
16 May 22
Entry into a Material Definitive Agreement
9:49pm
424B5
bgwta90h
16 May 22
Prospectus supplement for primary offering
9:47pm